SC

Sri Chandana Modukuri

Active Director Director DIN 07689464
DIN 07689464 First appointment Sep 2017 Primary industry Chemicals and Materials
Unlock full profile Investments · shareholding · contact details
Current companies 4 active board seats
Past companies 1 historical roles
Total affiliations 5 Since Sep 2017
Shareholding value •••• Premium profile

About Sri Chandana Modukuri

Data last updated:

Sri Chandana Modukuri is a Director at Spanus Pharmaceuticals Private Limited (since 2019), Director at Psyne Healthcare Private Limited (since 2024) and Director at Logical Genesis And Innovation Centre Private Limited (since 2025), and holds 1 more current directorship. The companies operate in Chemicals and Materials, Healthcare and Pharma. The 2 current companies with reported revenue have a combined latest revenue of ₹3.67 Cr; the largest is Spanus Pharmaceuticals Private Limited at ₹2.83 Cr (FY 2022). Earlier, Sri Chandana Modukuri was a Director at Starus Pharmaceuticals Private Limited (2017–2020).

DIN 07689464
Primary Designation Director
Industry Chemicals and Materials
First Appointment 30 Sep 2017
Oldest Company Age 7 yrs
Largest company Spanus Pharmaceuticals Private Limited · ₹2.83 Cr (FY 2022)
Combined revenue ₹3.67 Cr across 2 companies

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director25 Jan 20192019₹2.83 Cr (FY 2022)Active
Psyne Healthcare Private Limited U85100TG2021PTC155816
Director27 May 20242021₹83.8 Lakh (FY 2025)Active
Director31 Oct 20252025Active
Sarath Meditech Private Limited U24100TG2022PTC166614
Additional Director23 May 20252022Active

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director30 Sep 20172016₹15.05 Cr (FY 2022)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Spanus Pharmaceuticals Private Limited
Logical Genesis And Innovation Centre Private Limited
Sarath Meditech Private Limited
Psyne Healthcare Private Limited
Premium access

Shareholding and investment profile for Sri Chandana Modukuri

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sri Chandana Modukuri

Sri Chandana Modukuri currently holds 4 directorships: Spanus Pharmaceuticals Private Limited (Director, since 25 Jan 2019, revenue ₹2.83 Cr (FY 2022)); Psyne Healthcare Private Limited (Director, since 27 May 2024, revenue ₹83.8 Lakh (FY 2025)); Logical Genesis And Innovation Centre Private Limited (Director, since 31 Oct 2025); Sarath Meditech Private Limited (Additional Director, since 23 May 2025).

Sri Chandana Modukuri was first appointed on 30 Sep 2017 as Director at Starus Pharmaceuticals Private Limited. The most recent appointment on record is 31 Oct 2025 at Logical Genesis And Innovation Centre Private Limited.

The 2 current companies of Sri Chandana Modukuri that report revenue have a combined latest revenue of ₹3.67 Cr: Spanus Pharmaceuticals Private Limited ₹2.83 Cr (FY 2022); Psyne Healthcare Private Limited ₹83.8 Lakh (FY 2025).

Sri Chandana Modukuri held 1 earlier board appointment: Starus Pharmaceuticals Private Limited (Director, 30 Sep 2017 to 14 Feb 2020).

The current boards of Sri Chandana Modukuri's companies include Rama Subrahmanyam Sana (Spanus Pharmaceuticals Private Limited), Udaya Kiran Perla (Spanus Pharmaceuticals Private Limited), Hemanth Kobbanna (Psyne Healthcare Private Limited), Tanmayee Reddy Sama (Logical Genesis And Innovation Centre Private Limited), Srinivasa Babu Yadala (Sarath Meditech Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available